2006年毕业于北京大学医学部基础医学专业，并在北京大学心血管研究所完成2年的科研培训(导师为刘国庆教授)，于2008年7月获得荷兰莱顿大学生物药学硕士(导师为Theo J.C. Van Berkel教授和Miranda Van Eck教授)。随后师从前荷兰内分泌学会主席、阿姆斯特丹医学院大内科主任J.A.Romijn教授和欧洲脂蛋白研究协会主席Patrick Rensen教授，在荷兰莱顿大学医学研究中心内分泌科和代谢学系攻读博士学位(top5%优秀博士毕业生)，后在莱顿大学医学院和荷兰格罗宁根大学医学研究中心进行博士后研究，从2016年起成为荷兰莱顿大学医学研究中心高级研究人员、课题组负责人、并组建研究团队，主持完成2项荷兰国家级基金项目：主持荷兰国家自然基金(NWO)创新研究计划Veni项目(25万欧元，资助3年)，主持荷兰健康研究与发展组织(ZonMw)青年科学家项目(3万欧元，资助1年)；主持1项校级重点科研项目：荷兰莱顿大学基金(LUF)项目(2.5万欧元，资助18个月)。2019年，入选国家级青年人才项目计划。

全职回国3年多来，依托西安交通大学西部创新港Med-X研究院免疫代谢性疾病研究所、西安交通大学第一附属医院内分泌科和西安交通大学国际肥胖与代谢性疾病研究中心，开展肠道菌群及代谢产物预防和治疗代谢性疾病，包括动脉硬化性心血管疾病、糖尿病和非酒精性脂肪肝病的基础和临床研究。团队成员包括3位教授，7位讲师或博士后，10名科研助理和数十名研究生。申请人指导7名博士研究生(4名已毕业)，7名硕士研究生(5名已毕业)。已发表50篇SCI学术论文，近五年以通讯作者在Gut、Cell Reports Medicine、Cardiovascular Research、Pharmacological Research、ATVB、JCI Insight、Diabetes、eLife等专业领域顶尖期刊发表论文12篇。研究结果累计被引用超过2000余次，h指数22。主持2项国家级基金项目；2项省级基金项目；2项校/院级基金项目。

联系方式：y_wang@xjtufh.edu.cn

yanan.wang@xjtu.edu.cn

教育经历

工作经历

研究方向

      1. 脂质和脂蛋白代谢与代谢性疾病（包括肥胖、2型糖尿病、动脉粥样硬化性心血管疾病、非酒精性脂肪肝病）发生发展的基础和临床研究

      2. 能量稳态和脂肪功能调控与筛选代谢性疾病诊断和治疗的新靶标

      3. 探索肠道菌群及代谢产物治疗代谢性疾病的新型个体化方案

研究平台

论文和著作

1. Li Z, Yi CX, Katiraei S, Kooijman S, Zhou E, Chung CK, Gao Y, van den Heuvel JK, Meijer OC, Berbée JF, Heijink M, Giera M, Willems van Dijk K, Groen AK, Rensen PCN, Wang Y. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. Gut 2018 Jul; 67(7): 1269-1279 （通讯作者）.

- Highly cited paper according to Web of Science; top 1% of academic field.

- Received a research highlight editorial: Fluitman KS, Wijdeveld M, Nieuwdorp M, IJzerman RG. Potential of butyrate to influence food intake in mice and men. Gut 2018 Jul; 67(7): 1203-1204.

- Won the 2018 NASO (Netherlands Association for the Study of Obesity) Best Publication Prize.

2. Li Z, Zhou E, Liu C, Wicks H, Yildiz S, Razack F, Ying Z, Kooijman S, Koonen DPY, Heijink M, Kostidis S, Giera M, Sanders I, Kuijper EJ, Smits WK, van Dijk KW, Rensen PCN, Wang Y. Dietary butyrate ameliorates metabolic health associated with selective proliferation of gut Lachnospiraceae bacterium 28-4. JCI Insight. 2023;8(4). （通讯作者）

3. Liu C, Song Z, Li Z, Boon MR, Schönke M, Rensen PCN, Wang Y. Dietary choline increases brown adipose tissue activation markers and improves cholesterol metabolism in female APOE*3-Leiden.CETP mice. Int J Obes (Lond). 2023. （通讯作者）

4. Liu C, Schönke M, Spoorenberg B, Lambooij JM, van der Zande HJP, Zhou E, Tushuizen ME, Andreasson AC, Park A, Oldham S, Uhrbom M, Ahlstedt I, Ikeda Y, Wallenius K, Peng XR, Guigas B, Boon MR, Wang Y*, Rensen PCN*. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis. Elife. 2023;12. （共同通讯作者）

5. Liu C, Li Z, Song Z, Fan X, Shao H, Schönke M, Boon MR, Rensen PCN, Wang Y. Choline and butyrate beneficially modulate the gut microbiome without affecting atherosclerosis in APOE*3-Leiden.CETP mice. Atherosclerosis. 2022;362:47-55. （通讯作者）

6. He M, Wang J, Liang Q, Li M, Guo H, Wang Y, Deji C, Sui J, Wang YW, Liu Y, Zheng Y, Qian B, Chen H, Ma M, Su S, Geng H, Zhou WX, Guo X, Zhu WZ, Zhang M, Chen Z, Rensen PCN, Hui CC, Wang Y#, Shi B#.  Time-restricted eating with or without low-carbohydrate diet reduces visceral fat and improves metabolic syndrome: A randomized trial. Cell Rep Med. 2022 Oct 18;3(10):100777. （共同通讯作者）

7. Zhou E, Li Z, Nakashima H, Liu C, Ying Z, Foks AC, Berbee JFP, van Dijk KW, Rensen PCN, Wang Y. Hepatic Scavenger Receptor Class B Type 1 Knockdown Reduces Atherosclerosis and Enhances the Antiatherosclerotic Effect of Brown Fat Activation in APOE*3-Leiden.CETP Mice. Arterioscler Thromb Vasc Biol 2021 Apr;41(4): 1474-1486.（通讯作者）

8. Zhou E, Li Z, Nakashima H, Choukoud A, Kooijman S, Berbee JFP, Rensen PCN, Wang Y. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice. Pharmacol Res 2021 Mar 2;167: 105524.（通讯作者）

9. Zhou E, Hoeke G, Li Z, Eibergen AC, Schonk AW, Koehorst M, Boverhof R, Havinga R, Kuipers F, Coskun T, Boon MR, Groen AK, Rensen PCN, Berbée JFP, Wang Y. Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidemia and atherosclerosis development. Cardiovasc Res 2020 Aug 1;116(10): 1710-1720. （通讯作者）

10. Van der Tuin S, Li Z, Berbée JF, Verkouter I, Ringnalda LE, Neele AE, van Klinken JB, Rensen SS, Fu J, de Winther MPJ, Groen AK, Rensen PCN, Willems van Dijk K, Wang Y.  Lipopolysaccharide lowers cholesteryl ester transfer protein by activating F4/80⁺Clec4f⁺Vsig4⁺Ly6C^- Kupffer cell subsets. J Am Heart Assoc 2018 Mar;10: 7(6). （通讯作者）

11. Van der Tuin SJ, Kühnast S, Berbée JF, Verschuren L, Pieterman EJ, Havekes LM, van der Hoorn JW, Rensen PC, Jukema JW, Princen HM, Willems van Dijk, Wang Y.  Anacetrapib reduces (V) LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. J Lipid Res 2015 Nov; 56: 2085-2093. （通讯作者）

- Received a research highlight commentary: Barter PJ, Tabet F, Rye KA. Reduction in PCSK9 levels induced by anacetrapib: an off-target effect? J Lipid Res 2015;56:2045-2047.

12. Wang Y, van der Tuin S, Tjeerdema N, van Dam AD, Rensen SS, Hendrikx T, Berbée JF, Atanasovska B, Fu J, Hoekstra M, Bekkering S, Riksen NP, Buurman WA, Greve JW, Hofker MH, Shiri-Sverdlov R, Meijer OC, Smit JW, Havekes LM, van Dijk KW, Rensen PC. Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells. Hepatology 2015 Dec; 62: 1710-1722. （第一作者）

- This article has been recommended by Faculty of 1000 Prime as being of special significance in its field.

- Featured on cover and received a research highlight editorial: Haas JT, Staels B. Cholesteryl-ester transfer protein (CETP): A Kupffer cell marker linking hepatic inflammation with atherogenic dyslipidemia? Hepatology 2015; 62: 1659-1661.

13. Herrera Moro Chao D*, Wang Y*, Foppen E, Ottenhoff R, van Roomen C, Parlevliet ET, van Eijk M, Verhoek M, Boot R, Marques AR, Scheij S, Mirzaian M, Kooijman S, Jansen K, Wang D, Mergen C, Seeley RJ, Tschöp MH, Overkleeft H, Rensen PCN, Kalsbeek A, Aerts JMFG, Yi CX. . Diabetes 2019 Dec; 68(12): 2223-2234. [*Contributed equally] （共同一作）.

14. Kooijman S*, Wang Y*, Parlevliet ET*, Boon MR, Edelschaap D, Snaterse G, Pijl H, Romijn JA, Rensen PC. Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice. Diabetologia 2015 Nov; 58: 2637-2646 [*Contributed equally]. （共同一作）

15. Rozendaal YJW*, Wang Y*, Paalvast Y, Tambyrajah LL, Li Z, Willems van Dijk K, Rensen PCN, Kuivenhoven JA, Groen AK, Hilbers PAJ, van Riel NAW. In vivo and in silico dynamics of the development of Metabolic Syndrome. PLoS Comput Biol 2018 Jun; 14(6): e1006145. [*Contributed equally]. （共同一作）

- A press release by PLOS, entitled “New computational tool predicts progression of metabolic syndrome in mice”. AAAS and EurekAlert. Public release on 7-June-2018  

16. Wang Y, Parlevliet ET, Geerling JJ, Tuin SJL, Zhang H, Bieghs V, Jawad AHM, Shiri-Sverdlov R, Bot I, de Jager SC, Havekes LM, Romijn JA, Willems van Dijk K, Rensen PC. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br J Pharmacol 2014 Feb; 171: 723-734. （第一作者）

17. Wang Y, Snel M, Jonker JT, Hammer S, Lamb HJ, de Roos A, Meinders AE, Pijl H, Romijn JA, Smit JW, Jazet IM, Rensen PC. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases plasma CETP and increases apolipoprotein AI levels without improving the cholesterol efflux properties of HDL. Diabetes Care 2011 Dec; 34: 2576-2580. （第一作者）

18. Wang Y, Berbée JF, Stroes ES, Smit JW, Havekes LM, Romijn JA, Rensen PC. CETP expression reverses the reconstituted HDL-induced increase in VLDL. J Lipid Res 2011 Aug; 52: 1533-1541. （第一作者）

19. Liu C, Schönke M, Zhou E, Li Z, Kooijman S, Boon MR, Larsson M, Wallenius K, Dekker N, Barlind L, Peng XR, Wang Y, Rensen PCN. Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis. Cardiovasc Res. 2022 Jan 29;118(2):489-502

20. Trinder M, Wang Y, Madsen CM, Ponomarev T, Bohunek L, Daisely BA, Julia Kong H, Blauw LL, Nordestgaard BG, Tybjærg-Hansen A, Wurfel MM, Russell JA, Walley KR, Rensen PCN, Boyd JH, Brunham LR. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis. Circulation. 2021 Mar 2;143(9):921-934.

21. Liu C, Schonke M, Zhou E, Li Z, Kooijman S, Boon MR, Larsson M, Wallenius K, Dekker N, Barlind L, Peng XR, Wang Y, Rensen PCN. Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis. Cardiovasc Res 2022 Jan 29;118(2):489-502.

22. Blauw LL, Wang Y, Willems van Dijk K, Rensen PCN. A Novel Role for CETP as Immunological Gatekeeper: Raising HDL to Cure Sepsis? Trends Endocrinol Metab 2020 May;31(5):334-343.

23. Schilperoort M, van den Berg R, Coomans CP, Khedoe PPSJ, Ramkisoensing A, Boekestijn S, Wang Y, Berbée JFP, Meijer JH, Biermasz NR, Rensen PCN, Kooijman S. Continuous Light Does Not Affect Atherosclerosis in APOE*3-Leiden.CETP Mice. J Biol Rhythms 2020 Dec;35(6):598-611.

24. Körner A, Zhou E, Müller C, Mohammed Y, Herceg S, Bracher F, Rensen PCN, Wang Y, Mirakaj V, Giera M. Inhibition of Δ24-dehydrocholesterol reductase activates pro-resolving lipid mediator biosynthesis and inflammation resolution. Proc Natl Acad Sci U S A 2019 Oct; 116(41): 20623-20634

25. van Eyk HJ, Blauw LL, Bizino MB, Wang Y, van Dijk KW, de Mutsert R, Smit JWA, Lamb HJ, Jazet IM, Rensen PCN. Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort. Sci Rep 2019 Jul; 9(1): 9996